Then, we performed an in vitro study to explore the hypothesis that E2 treatment could protect mitochondrial function, reduce lipid oxidation, and prevent hepatic steatosis by upregulating the ERα/SIRT1/PGC-1α pathway. Here, PPARGC1A is linked to fatty liver disease.